| Method | Read length | Accuracy (single read not consensus) | Reads per run | Time per run | Cost per 1 billion bases (in US$) | Advantages | Disadvantages |
|---|---|---|---|---|---|---|---|
| Single-molecule real-time sequencing (Pacific Biosciences) Long-Read | 30,000 bp (N50); | 87% raw-read accuracy[82] | 4,000,000 per Sequel 2 SMRT cell, 100–200 gigabases[79][83][84] | 30 minutes to 20 hours[79][85] | $7.2-$43.3 | Fast. Detects 4mC, 5mC, 6mA.[86] | Moderate throughput. Equipment can be very expensive. |
| Ion semiconductor (Ion Torrent sequencing) | up to 600 bp[87] | 99.6%[88] | up to 80 million | 2 hours | $66.8-$950 | Less expensive equipment. Fast. | Homopolymer errors. |
| Pyrosequencing (454) | 700 bp | 99.9% | 1 million | 24 hours | $10,000 | Long read size. Fast. | Runs are expensive. Homopolymer errors. |
| Sequencing by synthesis (Illumina) | MiniSeq, NextSeq: 75–300 bp; MiSeq: 50–600 bp; HiSeq 2500: 50–500 bp; HiSeq 3/4000: 50–300 bp; HiSeq X: 300 bp | 99.9% (Phred30) | MiniSeq/MiSeq: 1–25 Million; NextSeq: 130-00 Million; HiSeq 2500: 300 million – 2 billion; HiSeq 3/4000 2.5 billion; HiSeq X: 3 billion | 1 to 11 days, depending upon sequencer and specified read length[89] | $5 to $150 | Potential for high sequence yield, depending upon sequencer model and desired application. | Equipment can be very expensive. Requires high concentrations of DNA. |
| Combinatorial probe anchor synthesis (cPAS- BGI/MGI) | BGISEQ-50: 35-50bp; MGISEQ 200: 50-200bp; BGISEQ-500, MGISEQ-2000: 50-300bp[90] | 99.9% (Phred30) | BGISEQ-50: 160M; MGISEQ 200: 300M; BGISEQ-500: 1300M per flow cell; MGISEQ-2000: 375M FCS flow cell, 1500M FCL flow cell per flow cell. | 1 to 9 days depending on instrument, read length and number of flow cells run at a time. | $5– $120 | ||
| Sequencing by ligation (SOLiD sequencing) | 50+35 or 50+50 bp | 99.9% | 1.2 to 1.4 billion | 1 to 2 weeks | $60–130 | Low cost per base. | Slower than other methods. Has issues sequencing palindromic sequences.[91] |
| Nanopore Sequencing Long-Read | Dependent on library preparation, not the device, so user chooses read length (up to 2,272,580 bp reported[92]). | ~92–97% single read | dependent on read length selected by user | data streamed in real time. Choose 1 min to 48 hrs | $7–100 | Longest individual reads. Accessible user community. Portable (Palm sized). | Lower throughput than other machines, Single read accuracy in 90s. |
| GenapSys Sequencing | Around 150 bp single-end | 99.9% (Phred30) | 1 to 16 million | Around 24 hours | $667 | Low-cost of instrument ($10,000) | |
| Chain termination (Sanger sequencing) | 400 to 900 bp | 99.9% | N/A | 20 minutes to 3 hours | $2,400,000 | Useful for many applications. | More expensive and impractical for larger sequencing projects. This method also requires the time-consuming step of plasmid cloning or PCR. |
This blog contains short learning projects I will carry out during my Scientist Training Programme. Each publication will start with an introduction highlighting background and motivation follow by results and discussion to finish with some reflection when possible.
Friday, 23 April 2021
Personal notes about NGS.
Sunday, 11 April 2021
What is more important - the individual privacy right or the wellbeing for society?
During my attendance at the National Information Governance training module, I found myself contemplating how data protection regulations in the UK specifically apply to genetic data. My curiosity was piqued by the potential challenges that UK rules governing the use of such data might pose to legitimate healthcare and research applications. This concern is grounded in the understanding that the sharing of genomic data can profoundly enhance medical research and healthcare delivery. The benefits of genomic data sharing are immense, especially when it comes to clinical geneticists comparing uncertain genetic results with existing databases. This comparative approach can often lead to more precise diagnoses, improved disease management, and consequently, enhanced healthcare services. To continually reap these benefits, it's essential to augment the size and diversity of genomics databases. I must admit that I'm not an expert in this area, but my preliminary reading leads me to conclude that there exists a legal gray zone. Striking the right balance between individual rights and the societal imperative of sharing genetic information seems to be a nuanced challenge. It appears that there's a lack of definitive guidance, with different laboratories interpreting the law in subtly distinct ways. The multifaceted nature of this issue allows for various approaches. Central to the debate is the question of whether we can truly identify a person through genetic data. Personal identifiable data is a double-edged sword: it possesses immense intrinsic value but can also be employed maliciously to discriminate or stigmatize individuals. A critical task is defining what constitutes identifiable versus de-identified data, as the current law makes distinctions based on these categories. For instance, if genetic data is deemed neither confidential nor identifiable, the law may permit more liberal sharing. Regrettably, these challenges are not solely technical in nature. The understanding of this complex issue extends into the realms of politics and philosophy. We must grapple with a profound question: What takes precedence, individual privacy rights or societal wellbeing? The stance taken on this question will have significant ramifications for the future of clinical genetics and my professional development. Furthermore, it's vital to recognize the political dimension to this discourse. Advocates for enhanced data sharing may perceive existing protections, such as anonymization coupled with managed access, as more robust than those primarily concerned with safeguarding individual privacy rights. The stakes in this debate are elevated, as the implications for healthcare and society are far-reaching, contingent upon the vision that is ultimately embraced.